Provided by Tiger Trade Technology Pte. Ltd.

Accendra Health Inc

0.4432
-0.0297-6.28%
Post-market: 0.4409-0.0023-0.52%16:43 EDT
Volume:1.38M
Turnover:621.26K
Market Cap:34.08M
PE:-0.11
High:0.4861
Open:0.4759
Low:0.4350
Close:0.4729
52wk High:5.60
52wk Low:0.4350
Shares:76.90M
Float Shares:56.51M
Volume Ratio:0.78
T/O Rate:2.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9457
EPS(LYR):-14.3179
ROE:-198.35%
ROA:0.64%
PB:-0.06
PE(LYR):-0.03

Loading ...

Bank of America Corp Reports 10.8% Passive Stake in Accendra Health as of Sept 30 - SEC Filing

THOMSON REUTERS
·
Oct 07

Accendra Health Sets Oct. 5 Start Date for Incoming CEO Kenneth Gardner-Smith

Reuters
·
Sep 29

Analysts Conflicted on These Healthcare Names: Petmed Express (PETS) and Accendra Health (ACH)

TIPRANKS
·
Sep 21

Accendra Health Names Kenneth Gardner-Smith as Next CEO, Effective Q4 2026

Reuters
·
Sep 17

Accendra Health, - Kenneth Gardner-Smith Expected to Assume CEO Role Early in Q4 2026

THOMSON REUTERS
·
Sep 17

Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth

THOMSON REUTERS
·
Sep 17

Accendra Health, - Edward Pesicka to Retire from Board When Gardner-Smith Assumes CEO Role

THOMSON REUTERS
·
Sep 17

Avon Technologies: Buy Rating Reiterated on New US$20.3m ACH GEN II Order and Unchanged $2390 Price Target

TIPRANKS
·
Sep 02

Press Release: HashKey Announces 2026 Interim Results

Dow Jones
·
Aug 27

Accendra Health updates capital allocation, CEO succession plans

TIPRANKS
·
Aug 17

Accendra Health Sells First of Two Non-Core Assets, Expects About $45 Million Cash Injection

Reuters
·
Aug 17

Accendra Health - Sale of Two Non-Core Assets to Provide $45 Mln Cash Injection in Q3 and Q4

THOMSON REUTERS
·
Aug 17

Accendra Health - Will not Implement At-the-Market Issuance Program

THOMSON REUTERS
·
Aug 17

Accendra Health - Board Expects to Announce CEO Successor by Mid-September 2026

THOMSON REUTERS
·
Aug 17

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

THOMSON REUTERS
·
Aug 17

Accendra Health Inc : UBS Cuts Target Price to $1.5 from $4.5

THOMSON REUTERS
·
Aug 14

Accendra Health is Maintained at Neutral by UBS

Dow Jones
·
Aug 14

UBS Adjusts Price Target on Accendra Health to $1.50 From $4.50, Keeps Neutral Rating

MT Newswires Live
·
Aug 13

U.S. Research Roundup-Airbnb, Five Below, Silgan Holdings

Reuters
·
Aug 13

Press Release: Chemtrade Logistics Income Fund Announces Results for the Second Quarter of 2026 and Reiterates 2026 Adjusted Ebitda Guidance of $485 to $525 Million

Dow Jones
·
Aug 13